Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Clinical trial NCT07711002 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07711002
- Sponsor
- AstraZeneca
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-01
- Primary completion
- 2031-06-17
- Enrollment
- 1330
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.